AGTC to Present at the 2021 Cantor Fitzgerald Virtual Global Healthcare Conference
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology firm focused on gene therapies for inherited retinal diseases, announced that CEO Sue Washer will participate in a fireside chat at the 2021 Cantor Fitzgerald Virtual Global Healthcare Conference on September 30, 2021, at 1:20 PM ET.
Investors can access the audio webcast at http://ir.agtc.com/eventsand-presentations, with a replay available afterward on AGTC's website. The company has ongoing clinical trials for X-linked retinitis pigmentosa and achromatopsia.
Details
News Market Reaction – AGTC
The recorded move for AGTC in the trading session of this news was +0.31%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
GAINESVILLE, Fla. and CAMBRIDGE, Mass., Sept. 27, 2021 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare inherited retinal diseases (IRDs), today announced that Sue Washer, President and Chief Executive Officer of AGTC, will be participating in a fireside chat at the 2021 Cantor Fitzgerald Virtual Global Healthcare Conference at 1:20pm ET on Thursday, September 30th, 2021.
An audio webcast of the presentation can be accessed by visiting http://ir.agtc.com/eventsand-presentations. A replay will be available on the Company's website, http://agtc.com, following the event.
About AGTC
AGTC is a clinical-stage biotechnology company developing genetic therapies for people with rare and debilitating ophthalmic, otologic and central nervous system (CNS) diseases. AGTC is a leader in designing and constructing all critical gene therapy elements and bringing them together to develop customized therapies with the potential to address real patient needs. AGTC’s most advanced clinical programs leverage its best-in-class technology platform to potentially improve vision for patients with an inherited retinal disease. AGTC has active clinical trials in X-linked retinitis pigmentosa (XLRP) and achromatopsia (ACHM CNGB3 and ACHM CNGA3). Its preclinical programs build on the Company’s industry leading AAV manufacturing technology and scientific expertise. AGTC is also advancing multiple important pipeline candidates to address substantial unmet clinical need in optogenetics, otology and CNS disorders, including entering into strategic partnerships with companies including Otonomy, Inc., a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, and Bionic Sight, LLC, an innovator in the emerging field of optogenetics and retinal coding.
IR CONTACT:
Jonathan Nugent
Stern IR
T: 212-698-8698
jonathan.nugent@sternir.com
Corporate Contacts:
Jonathan Lieber
Chief Financial Officer
Applied Genetic Technologies Corporation
T: (617) 843-5778
jlieber@agtc.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.